A COMPARISON OF TOXICITY AND SUPPORTIVE CARE USE BETWEEN FOUR CYTOTOXIC AGENTS USED IN THE MANAGEMENT OF METASTATIC BREAST CANCER (MBC))
Author(s)
Dranitsaris G1, Knoth RL2, Cox D2, Faria C2
1Augmentium Pharma Consulting, Toronto, ON, Canada, 2Eisai, Inc., Woodcliff Lake, NJ, USA
OBJECTIVES: Capecitabine (C), gemcitabine (G) and vinorelbine (V) are commonly used as single agents in patients with MBC. Eribulin (E) is among the most recent cytotoxic agents to gain regulatory approval for MBC in the United States (U.S.) as a single agent. In this analysis, toxicity and supportive care use was compared between the four agents in a sample of MBC patients treated in a U.S. community oncology setting. METHODS:
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PCN16
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Oncology